SCHEMBL336009

SCHEMBL336009

CC(=O)c1ccc(N2CCN(C)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.65
RAB9A P51151 5/20 0.65
LMNA P02545 2/20 0.65
TP53 P04637 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
KMT2A Q03164 4/20 0.63
ALDH1A1 P00352 4/20 0.63
MAPT P10636 4/20 0.63
HDAC3 O15379 3/20 0.58
HDAC8 Q9BY41 3/20 0.58
MEN1 O00255 2/20 0.58
KDM4E B2RXH2 1/20 0.55
GAA P10253 1/20 0.55
ADRA2C P18825 1/20 0.55
GFER P55789 1/20 0.55
PTK2B Q14289 1/20 0.55
ESR2 Q92731 1/20 0.55
CHEK1 O14757 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15801114 0.92 MAPT (0.71) NPC1RAB9ALMNATP53SMN1; SMN2
SCHEMBL17669252 0.92 MAPT (0.71) NPC1RAB9ALMNATP53SMN1; SMN2
SCHEMBL4625472 0.89 MAPT (0.55) NPC1RAB9ALMNATP53SMN1; SMN2
SCHEMBL19771379 0.86 NPC1 (0.83) NPC1RAB9ALMNATP53SMN1; SMN2
SCHEMBL9531913 0.85 NPC1 (0.68) NPC1RAB9ALMNATP53SMN1; SMN2
SCHEMBL63450 0.85 CHEK1 (0.70) NPC1RAB9ALMNATP53SMN1; SMN2
SCHEMBL15156349 0.84 MAPT (0.62) NPC1RAB9ALMNATP53SMN1; SMN2
SCHEMBL909633 0.84 MAPT (0.62) NPC1RAB9ALMNATP53SMN1; SMN2
SCHEMBL62896 0.83 NPC1 (0.63) NPC1RAB9ALMNATP53SMN1; SMN2
Hydrochloric Acid SCHEMBL1222378 0.83 CHEK1 (0.68) NPC1RAB9ALMNATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) 2024-01-18 US disclosed
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) 2024-01-18 US disclosed
US-20230301984-A1 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-09-28 US disclosed
US-20230301984-A1 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-09-28 US disclosed
EP-3405477-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-07 EP disclosed
WO-2023073115-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-05-04 WO disclosed
US-20230015617-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2023-01-19 US disclosed
US-11160803-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2021-11-02 US disclosed
US-11072634-B2 Inhibitors of transglutaminases ZEDIRA GMBH (DE) 2021-07-27 US disclosed
US-11046657-B2 Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-06-29 US disclosed
WO-2004020441-A1 HETEREOARYL NITRILE DERIVATIVES NOVARTIS AG (CH) 2004-03-11 WO disclosed
EP-0250193-B1 Photoreactive lenses MARCONI GEC LTD (GB) 1993-10-27 EP disclosed
EP-0099329-B1 DITHIO COMPOUNDS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE Zyma SA (CH) 1990-10-31 EP disclosed
US-4946861-A TREATMENT OF LIVER DISORDERS ZYMA SA (CH) 1990-08-07 US disclosed
US-4818765-A TREATING LIVER, RESPIRATORY TRACT, VASCULAR DISORDERS CIBA-GEIGY CORPORATION (US) 1989-04-04 US disclosed
US-4818096-A SUNGLASSES; BENZO OR NAPHTHOPYRANS WITH NITROGEN CONTAINING SUBSTITUENTS THE PLESSEY COMPANY PLC (GB) 1989-04-04 US disclosed
EP-0099329-A1 Dithio compounds, pharmaceutical preparations containing them and their use Zyma SA (CH) 1984-01-25 EP disclosed
US-4053470-A BACTERICIDES, ANTIBIOTICS PARKE, DAVIS & COMPANY (US) 1977-10-11 US disclosed
US-3954734-A PENICILLIN AND CEPHALOSPORIN TYPE PARKE, DAVIS & COMPANY 1976-05-04 US disclosed
US-3951982-A Trialkylsilyl esters of 6(substituted amino)phenyl-1,-dihydro-2-oxonicotinic acid, methods for their production and conversion to the corresponding acid chlorides PARKE, DAVIS & COMPANY 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11160803-B2 Phthalazinone derivatives NR0B1, NR0B2, NR2E1 NPC1 1933/4885RAB9A 3332/4885LMNA 2854/4885
US-20240016775-A1 ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR PARP3, PARP1, PARP4 NPC1 1634/4885RAB9A 2788/4885LMNA 370/4885
US-11046657-B2 Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines CCL5, CXCR3, CXCL10 NPC1 3576/4885RAB9A 2968/4885LMNA 3912/4885
US-20230301984-A1 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION ALDH1A2, PDE6D, PDE6C NPC1 35/4885RAB9A 1184/4885LMNA 192/4885
US-20230015617-A1 PHTHALAZINONE DERIVATIVES NR0B1, NR0B2, NR2E1 NPC1 1989/4885RAB9A 3570/4885LMNA 2988/4885
US-11072634-B2 Inhibitors of transglutaminases TGM2, TGM3, TGM1 NPC1 2562/4885RAB9A 1872/4885LMNA 2426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.